Sensus Healthcare, Inc. (SRTS) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sensus Healthcare Reports First Quarter Financial Results Featuring 37% Revenue Growth
May 3, 2018 4:00 PM EDTBOCA RATON, Fla., May 3, 2018 /PRNewswire/ --Â Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces financial results for the three months ended March 31, 2018.
Highlights from the first quarter of 2018 and recent weeks include:
Achieved 10 consecutive quarters of double-digit revenue growth, with revenues up 37% year over year to $6.0 million Shipped 21 systems including 12 SRT-100 Vision systems, bringing the worldwide installed base to 350 units; more than 70 centers are using SRT systems to treat... More